✉news HealthMedicine first seen 7 d ago, last 7 d ago, peak #23
Eli Lilly Advances New Diabetes and Weight Loss Drug to Phase 3
Original: Eli Lilly: Another High-Efficacy Diabetes and Weight Loss Medicine Advancing to Phase 3
Eli Lilly has moved another high-efficacy medicine for diabetes and weight loss into Phase 3 clinical trials. The drugmaker, already riding the success of its GLP-1 treatments, is expanding its pipeline of obesity and diabetes therapies. The announcement underscores intensifying competition in the booming market for weight loss medications, where demand continues to outpace supply.
Why now: Ongoing investor and public interest in Eli Lilly's obesity and diabetes drug pipeline amid fierce competition in the weight loss market
Evidence
- Eli Lilly: Another High-Efficacy Diabetes and Weight Loss Medicine Advancing to Phase 3 · Morningstar
API: https://socialmediatrends-api.osmike.com/v1/trends/4158658